Stocks
Trilogy Capital Trims Amgen Holdings by 92% in Q2
Amgen Inc., a global biotechnology company, saw its stock holdings trimmed by Trilogy Capital Inc. in the second quarter, according to a recent 13F filing with the Securities and Exchange Commission (SEC). The fund reduced its Amgen holdings by 91.8%, selling 9,302 shares during the quarter.
As a result of the sale, Trilogy Capital's holdings in Amgen were worth $302,000 at the end of the most recent quarter. The company owned 833 shares of Amgen's stock after the reduction.
Other institutional investors and hedge funds have also made adjustments to their stakes in AMGN. Robeco Institutional Asset Management B.V. boosted its holdings in Amgen by 10% in the fourth quarter, increasing its position to 481,453 shares worth $157,584,000.